We are live on ! Find out more
NTLA icon

Intellia Therapeutics

141 hedge funds and large institutions have $430M invested in Intellia Therapeutics in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 40 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $2.21M | Put options by funds: $1.43M

5.23% more ownership

Funds ownership: 67.37%72.6% (+5.2%)

5% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 40

10% less funds holding

Funds holding: 157141 (-16)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

42% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 36

48% less capital invested

Capital invested by funds: $833M → $430M (-$403M)

Holders
141
Holders Change
-16
Holders Change %
-10.19%
% of All Funds
3.14%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
21
Increased
42
Reduced
40
Closed
36
Calls
$2.21M
Puts
$1.43M
Net Calls
+$777K
Net Calls Change
+$4.25M
Name Holding Trade Value Shares
Change
Change in
Stake
AIM
1
ARK Investment Management
Florida
$92.8M +$19.5M +1,048,162 +18%
BlackRock
2
BlackRock
New York
$39.2M +$2.31M +124,341 +5%
Vanguard Group
3
Vanguard Group
Pennsylvania
$37.5M +$1.73M +92,961 +4%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$33M -$850K -45,714 -2%
State Street
5
State Street
Massachusetts
$31.6M +$4.6M +247,333 +12%
Morgan Stanley
6
Morgan Stanley
New York
$30.5M +$4.87M +262,189 +13%
OTPPB
7
Ontario Teachers' Pension Plan Board
Ontario, Canada
$22.7M +$30.9M +1,660,000 New
AVAI
8
Atlas Venture Associates IX
Massachusetts
$22M
Temasek Holdings
9
Temasek Holdings
Singapore
$10.8M
Chevy Chase Trust
10
Chevy Chase Trust
Maryland
$9.49M -$868K -46,688 -6%
Federated Hermes
11
Federated Hermes
Pennsylvania
$9.11M -$9.76K -525 -0.1%
Deutsche Bank
12
Deutsche Bank
Germany
$8.68M +$3.2M +172,309 +37%
ROTUOC
13
Regents of the University of California
California
$7.16M
Northern Trust
14
Northern Trust
Illinois
$5.32M -$71.4K -3,839 -1%
O
15
OrbiMed
New York
$5.15M -$6.82M -367,000 -49%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$4.91M +$330K +17,771 +5%
Citigroup
17
Citigroup
New York
$3.73M +$2.37M +127,275 +87%
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$3.55M +$4.03M +217,071 +503%
Lord, Abbett & Co
19
Lord, Abbett & Co
New Jersey
$3.42M +$1.58M +85,124 +52%
Renaissance Technologies
20
Renaissance Technologies
New York
$3.11M +$4.24M +228,000 New
UBS Group
21
UBS Group
Switzerland
$2.79M +$1.24M +66,702 +48%
Charles Schwab
22
Charles Schwab
California
$2.34M -$39.9K -2,144 -1%
Goldman Sachs
23
Goldman Sachs
New York
$2.21M +$1.19M +64,134 +66%
TCM
24
Tekla Capital Management
Massachusetts
$2.05M +$1.52M +81,619 +119%
Two Sigma Investments
25
Two Sigma Investments
New York
$2.02M +$2.76M +148,261 New

NTLA Hedge Fund Activity: Q4 2018 in Review

141 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2018, worth a combined $430M — down 48% from $833M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of NTLA and 21 opened new positions — a net loss of 15 holders — while 40 trimmed existing stakes and 42 added.

The largest buyer was Ontario Teachers' Pension Plan Board, opening a new position worth an estimated $30.9M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $15.7M sold.

  • 141 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2018, down from 157 in Q3 2018.
  • Funds reported $430M of Intellia Therapeutics stock for Q4 2018, down 48% quarter-over-quarter.
  • 21 funds opened new Intellia Therapeutics positions in Q4 2018 and 36 closed out, a net change of -15 holders.
  • The largest Intellia Therapeutics buyer in Q4 2018 was Ontario Teachers' Pension Plan Board, an estimated $30.9M added.
  • The largest Intellia Therapeutics seller in Q4 2018 was Farallon Capital Management, an estimated $15.7M sold.

Based on aggregated 13F filings for Q4 2018.